ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent
BioSolutions (NYSE:EBS) announced today that, after completion of an
inter-agency In Process Review, the Biomedical Advanced Research
Development Authority (BARDA) of the U.S. Department of Health and Human
Services (HHS) has exercised a contract option to further advance the
development of PreviThraxTM
(Recombinant Protective Antigen Anthrax Vaccine, Purified), the
company’s novel rPA anthrax vaccine candidate. This option is part of
the company’s rPA development contract with BARDA executed in October
2010.

“Emergent is pleased that PreviThrax, our rPA vaccine candidate, has met
all of the key milestones necessary for BARDA to exercise the contract
option,” said Adam Havey, executive vice president of Emergent
BioSolutions. “We look forward to continuing to work with BARDA to
develop the medical countermeasures it believes are necessary to address
the nation’s security requirements.”

Since initiating the contract in 2010, Emergent has made significant
progress in the development of PreviThrax, including:

This work is being performed under Contract Number HHSO100201000059C,
funded by BARDA. The vaccine candidate is based on the pioneering work
of the U.S. Army Medical Research Institute of Infectious Diseases and
has previously received funding from the National Institute of Allergy
and Infectious Diseases.

About Emergent BioSolutions Inc.

Emergent BioSolutions protects and enhances life by developing and
manufacturing vaccines and therapeutics that are supplied to healthcare
providers and purchasers for use in preventing and treating disease.
Emergent’s marketed and investigational products target infectious
diseases, oncology and autoimmune disorders. Additional information
about the company may be found at www.emergentbiosolutions.com.
Follow us on Twitter @emergentbiosolu.

Safe Harbor Statement

This press release includes statements that are forward-looking. These
forward-looking statements include those regarding our expectations for
PreviThrax. These forward-looking statements are based on our current
intentions, beliefs and expectations regarding future events. We cannot
guarantee that any forward-looking statement will be accurate. Investors
should realize that if underlying assumptions prove inaccurate or
unknown risks or uncertainties materialize, actual results could differ
materially from our expectations. Investors are, therefore, cautioned
not to place undue reliance on any forward-looking statement. Any
forward-looking statement speaks only as of the date of this press
release, and, except as required by law, we do not undertake to update
any forward-looking statement to reflect new information, events or
circumstances.

Some important factors that could cause our actual results to differ
from our expectations in these forward-looking statements include:
appropriations for and our ability to win development contracts with the
U.S. government for PreviThrax and the inherent uncertainty of the
timing, success of, and expense associated with development, clinical
utility, regulatory approval and potential government procurement of
PreviThrax. The foregoing sets forth many, but not all, of the factors
that could cause actual results to differ from our expectations in any
forward-looking statement. Investors should consider this cautionary
statement, as well as the risk factors identified in our periodic
reports filed with the SEC, when evaluating our forward-looking
statements.